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A role for progesterone in breast carcinogenesis is 
increasingly recognized. Breast cancer risk increases with 
the number of menstrual cycles a women experiences [1] 
and proliferation occurs in the breast epithelium during 
the luteal phase, when serum progesterone levels are high 
[2]. Moreover, postmenopausal women on hormone 
replacement therapy have increased breast cancer risk 
when taking combined estrogens and progestins but not 
with estrogens only [3].
Receptor activator of NF-κB ligand (RANKL) is a 
tumor necrosis factor (TNF) family member originally 
identiﬁ ed as a dendritic cell survival factor involved in 
the regulation of T-cell-dependent immune response and 
subsequently shown to control bone remodeling by 
inducing osteoclast diﬀ erentiation [4]. Analysis of 
RANK- and RANKL-deﬁ cient mice pointed to a role for 
this pathway in the mammary gland during pregnancy [5] 
and in mammary carcinoma metastasis to the bone [6].
RANKL expression in the mammary epithelium is con-
trolled by progesterone [7,8]. Recent work identiﬁ ed 
RANKL as a key paracrine mediator of progesterone-
induced mouse mammary epithelial cell proliferation 
[9,10] and implicated the cytokine in stem cell control 
[11,12]. Systemic inhibition of RANKL signaling by intra-
venous injection of recombinant osteoprotegerin, its decoy 
recep tor, blocked progesterone-induced prolifera tion in 
the mammary epithelium, suggesting RANKL may be 
used as a therapeutic target in the mammary gland [9].
Schramek and colleagues [13] and Gonzalez-Suarez 
and colleagues [14] now induced mammary carcinomas 
in mice using the progestin medroxyprogesterone acetate 
(MPA) and the mutagenic agent 7,12-dimethylbenz(a)
anthracene (DMBA) and demonstrate that RANKL is a 
key factor in this process. Over-expression of RANK by 
means of a mouse mammary tumor virus (MMTV)-
driven transgene accelerated hyperplasia and tumor 
forma tion [14] whereas pharmacological inhibition of 
RANKL [13,14] and genetic inactivation of RANK in the 
mammary epithelium [14] decreased incidence and 
delayed onset of tumorigenesis in this system.
To investigate whether RANKL is similarly important 
in the pathogenesis of other tumor types that arise 
independently of exogenous hormones, Gonzalez-Suarez 
and colleagues used the MMTV-neu transgenic mouse 
model. Interestingly, in ErbB2-driven carcinogenesis, 
pharmacological inhibition of RANKL also reduces 
tumor growth and lung metastasis, suggesting that the 
RANK signaling pathway may be of functional relevance 
in a wider tumor spectrum. Th is is of great clinical 
interest given the heterogeneity of human breast cancer. 
Schramek and colleagues observe that RANK deletion 
does not alter the incidence of mammary cancer in 
MMTV-neuT transgenic mice. It is conceivable that the 
apparent discrepancy results from Keratin5-cre RANK 
deleted cells being outgrown by MMTV-neuT cells that 
have kept the wild-type RANK allele.
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Importantly, Gonzalez-Suarez and colleagues demon-
strate that Fc-RANK inhibits proliferation of normal 
mammary epithelium and hyperplasias, but not in carci-
nomas, suggesting RANKL inhibition would be useful in 
early stages of tumorigenesis and/or as a preventive drug.
Can these ﬁ ndings be extrapolated to humans? Disso-
ciation of hormone receptor expression and proliferation 
in the adult mammary gland is a phenomenon that is 
conserved between human and rodents (reviewed in 
[15]), suggesting that paracrine signals are also of 
relevance to the human breast. Caution is required as it is 
unclear whether the paracrine circuitry is shared between 
the two species or whether the human breast may rely on 
distinct factors.
Immunostainings of human breast carcinomas reveal 
that RANKL is expressed in 11% of human tumors. Th ere 
is no evidence for colocalization within the epithelium 
for receptor and ligand but expression is found in some 
stromal cells [14]. Th is raises the possibility that the 
scenario is more complex in human breast cancer than in 
the present mouse tumor models with inﬁ ltrating 
immune cells providing the ligand. In any case, this drug 
seems too palatable not to try! Th e challenge lies in 
designing clinical trials with short endpoints and 
identifying adequate preclinical models to identify swiftly 
which particular patients may beneﬁ t from the drug.
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